---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2025-12-28T10:44:49.231976'
end_time: '2025-12-28T10:47:10.591017'
duration_seconds: 141.36
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BRCA2
  gene_symbol: BRCA2
  uniprot_accession: P51587
  protein_description: 'RecName: Full=Breast cancer type 2 susceptibility protein
    {ECO:0000305}; AltName: Full=Fanconi anemia group D1 protein;'
  gene_info: Name=BRCA2 {ECO:0000312|HGNC:HGNC:1101}; Synonyms=FACD, FANCD1;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BRCA2. (IPR015525); BRCA2_hlx. (IPR015252); BRCA2_hlx_sf. (IPR036315);
    BRCA2_OB_1. (IPR015187); BRCA2_OB_2_dom. (IPR048262)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 57
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P51587
- **Protein Description:** RecName: Full=Breast cancer type 2 susceptibility protein {ECO:0000305}; AltName: Full=Fanconi anemia group D1 protein;
- **Gene Information:** Name=BRCA2 {ECO:0000312|HGNC:HGNC:1101}; Synonyms=FACD, FANCD1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BRCA2. (IPR015525); BRCA2_hlx. (IPR015252); BRCA2_hlx_sf. (IPR036315); BRCA2_OB_1. (IPR015187); BRCA2_OB_2_dom. (IPR048262)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BRCA2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BRCA2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BRCA2** (gene ID: BRCA2, UniProt: P51587) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

<think>
Let me carefully analyze what's being asked here. The user is asking for a comprehensive research report on the BRCA2 gene in humans (Homo sapiens, UniProt: P51587). 

First, let me verify:
1. Gene symbol: BRCA2 - this matches the UniProt description
2. Organism: Homo sapiens (Human) - correct
3. Description: Breast cancer type 2 susceptibility protein, also known as Fanconi anemia group D1 protein (FACD, FANCD1)
4. Key domains: Multiple BRCA2-specific domains including helical domains and OB folds

The extensive search results provided contain highly relevant primary literature on BRCA2 function. I have sources on:
- BRCA2 structure and mechanism of action
- DNA repair functions (homologous recombination)
- RAD51 mediator function
- BRCA2 protein domains and interactions
- Cell cycle regulation
- Replication fork protection
- Interactions with partner proteins (PALB2, RAD51, etc.)
- Cancer predisposition
- Various molecular mechanisms

This is NOT ambiguous - there is clear, extensive literature on BRCA2 in humans, and this is one of the most well-characterized genes related to hereditary cancer.

I need to write a comprehensive 10,000+ word research report following the structure outlined in the report_format section. Let me plan the major sections:

1. Introduction/Summary
2. Primary Function: DNA Repair and Genome Stability
3. Molecular Architecture and Domain Organization
4. Homologous Recombination Pathway
5. Replication Fork Protection
6. Cellular Localization and Nuclear Import
7. Cell Cycle Regulation of BRCA2
8. Protein-Protein Interactions and Complexes
9. Cancer Predisposition and Hereditary Breast/Ovarian Cancer
10. Clinical Applications and Therapeutic Implications


11. Conclusion

I'll synthesize the key insights from the comprehensive research, highlighting BRCA2's critical role in maintaining genomic integrity. The conclusion will emphasize the gene's significance in understanding cancer mechanisms, potential therapeutic interventions, and future research directions. I'll integrate the multifaceted aspects of BRCA2's function, from molecular interactions to clinical implications, providing a holistic perspective on this pivotal gene's importance in human health and disease.
</think>

# BRCA2: A Comprehensive Molecular and Functional Characterization of the Breast Cancer Type 2 Susceptibility Protein

**BRCA2** (breast cancer type 2 susceptibility protein, also known as Fanconi anemia group D1 protein) is a large, multifunctional tumor suppressor protein encoded on human chromosome 13 that serves as a critical mediator in homologous recombination-based DNA repair, replication fork protection, and genome stability maintenance. The BRCA2 protein (3,418 amino acids, approximately 384 kDa) functions primarily through a sophisticated molecular mechanism in which it acts as a recombination mediator by facilitating the recruitment and assembly of the RAD51 recombinase onto single-stranded DNA generated during DNA damage or replication stress, thereby enabling high-fidelity double-strand break repair through homologous recombination and interstrand crosslink repair. Beyond its canonical roles in recombination-mediated repair, BRCA2 participates in cell cycle checkpoint control, protects stalled replication forks from nucleolytic degradation through distinct mechanisms, and undergoes dynamic cell cycle-regulated modulation of its activity to coordinate DNA repair processes with cellular proliferation. The protein localizes exclusively to the cell nucleus through three conserved nuclear localization signals in its C-terminus, interacts with multiple partner proteins including PALB2, RAD51, DMC1, and DSS1 through distinct protein domains, and when functionally compromised through germline mutations, confers substantially elevated lifetime risks of breast cancer (>60%), ovarian cancer (13-29%), and pancreatic cancer (5-10%), establishing BRCA2 as a classical tumor suppressor gene whose loss of function drives genomic instability and malignant transformation.

## Protein Architecture and Molecular Domain Organization

### Overall Structure and Composition

The BRCA2 protein is an exceptionally large molecule composed of 3,418 amino acids that exhibits a highly modular architecture with distinct functional domains arranged in a linear sequence along the protein backbone[1][2]. Structurally, the protein functions as a dimer, a configuration that has been revealed through three-dimensional electron microscopy reconstructions and biochemical analysis[2]. The dimeric assembly of BRCA2 is not merely a passive oligomerization but rather a functionally significant state that enables the simultaneous recruitment of multiple copies of the RAD51 recombinase, with two oppositely-oriented sets of RAD51 molecules binding to each BRCA2 dimer[2]. This architectural arrangement appears to be critical for the protein's ability to nucleate RAD51 filament formation efficiently at multiple sites along single-stranded DNA, establishing a molecular mechanism by which BRCA2 can coordinate the assembly of the recombination machinery. The existence of these different oligomeric states—monomeric and dimeric forms—is not static but rather dynamically regulated by binding partners such as DSS1 (a small acidic protein that stabilizes the monomeric form) and single-stranded DNA, suggesting a model in which the oligomerization state of BRCA2 itself may be a regulated aspect of its cellular function[51].

### The Central BRC Repeat Region

The most extensively studied functional domain of BRCA2 is the central region containing eight tandem BRC (BRCA2 repeat containing) repeats, which spans approximately 1,127 amino acids within exon 11 and constitutes the primary interaction interface with the RAD51 recombinase[1][13][43]. These eight BRC repeats are arranged in a highly ordered manner and are highly conserved among mammalian species, suggesting ancient evolutionary importance for their functions[16][43]. The BRC repeats display a hierarchical organization with distinct functional specialization, as the upstream repeats BRC1-4 bind to free RAD51 monomers with high affinity and serve to stimulate RAD51-ssDNA complex formation while simultaneously inhibiting RAD51 binding to double-stranded DNA, thereby creating selectivity for the repair substrate[16][43]. In contrast, the downstream repeats BRC5-8 exhibit lower affinity for free RAD51 but preferentially bind to and stabilize RAD51 nucleoprotein filaments that have already assembled on ssDNA, supporting filament elongation and preventing disassembly[16][43]. This functional dichotomy suggests an evolutionary optimization in which BRC1-4 serve primarily to nucleate RAD51 filament assembly at the initiating stage, while BRC5-8 function to maintain and extend the growing filament during the critical early stages of strand invasion and homologous pairing.

The specificity of BRC repeat-RAD51 interaction has been illuminated by structural studies demonstrating that each BRC motif directly mimics the structure of a RAD51 monomer at its polymerization interface, allowing RAD51 molecules to bind to BRC repeats in a manner that facilitates subsequent protein-protein interactions and cooperative assembly[1][13]. The binding occurs through a series of hydrophobic and hydrophilic interactions that stabilize a β-hairpin structure of the BRC sequence against the oligomerization surface of RAD51[8]. Importantly, not all eight BRC repeats function identically; the first four BRC repeats are substantially more conserved across mammalian species and bind RAD51 with markedly higher affinity than the latter four repeats, consistent with biochemical evidence that demonstrates progressive decreases in RAD51 binding affinity from BRC1 through BRC8[16]. Some evidence suggests that the variable affinity among BRC repeats may reflect their specialized roles in sequestering or releasing RAD51 under different cellular conditions, representing an elegant molecular mechanism for fine-tuning the activity of this essential recombination protein.

### The C-Terminal DNA-Binding Domain

The C-terminal region of BRCA2 (CTD), spanning approximately 710 amino acids from residues 2,481 to 3,190, comprises the second major structural and functional element of the protein and contains the primary DNA-binding capacity[2][14]. This domain exhibits a complex hierarchical organization consisting of an α-helical domain located in the N-terminal portion followed by three oligonucleotide/oligosaccharide-binding (OB) folds designated OB1, OB2, and OB3[2][14]. The three OB folds within the BRCA2 C-terminal domain function cooperatively to achieve high-affinity single-stranded DNA binding, with OB2 and OB3 contributing more substantially to ssDNA binding affinity than OB1, consistent with structural and sequence conservation patterns[2][14]. The DNA-binding domain is capable of binding both single-stranded and double-stranded DNA, though it exhibits a clear preference for single-stranded DNA substrates[2]. Importantly, the BRCA2 C-terminal domain requires approximately 40 nucleotides of single-stranded DNA for weak binding and more than 70 nucleotides for maximal binding affinity, indicating that the domain functions optimally with relatively extended DNA substrates typical of those generated at sites of DNA damage[2].

The C-terminal domain also contains a secondary RAD51-interaction site distinct from the BRC repeats, positioned immediately adjacent to the DNA-binding domain[1][43]. This C-terminal RAD51-binding motif is subject to cell cycle-dependent phosphorylation at serine 3291 by cyclin A-CDK2 and cyclin B-CDK1, a modification that blocks the interaction between BRCA2 and RAD51 during interphase and early mitosis when DNA repair via homologous recombination is not required[38][41]. Upon DNA damage, this phosphorylation is rapidly suppressed, allowing RAD51 recruitment to this domain and promoting DNA repair[38][41]. This represents a sophisticated regulatory mechanism in which cell cycle control and DNA damage sensing are integrated to ensure that recombination-mediated repair is restricted to appropriate phases of the cell cycle.

### Nuclear Localization Signals

The extreme C-terminus of the BRCA2 protein contains three nuclear localization signals (NLS) that direct the protein to the cell nucleus and are essential for its biological function[1][7]. These NLS sequences are located at amino acid positions 3263-3269 (NLS1), 3311-3317 (NLS2), and 3381-3385 (NLS3), flanking the C-terminal RAD51-binding domain[1]. Only NLS1 is highly conserved across mammalian species, while NLS2 and NLS3 are less conserved, though all three are enriched in positively charged amino acid residues characteristic of classical nuclear localization signals[1]. The presence of multiple redundant NLS elements suggests functional importance, as defects in nuclear transport of BRCA2 resulting from mutations that disrupt these signals have been proposed as potential mechanisms of carcinogenesis in hereditary breast cancer patients[7]. The regulation of BRCA2 nuclear localization is not merely dependent on these intrinsic signals but is also controlled by its interaction with the DSS1 protein, which masks a nuclear export signal (NES) and thereby promotes nuclear accumulation[44].

## Primary Function: Recombination Mediator in Homologous Recombination Repair

### The Recombination Mediator Model

The fundamental biological function of BRCA2 is to act as a recombination mediator—a molecular facilitator that orchestrates the recruitment and nucleation of RAD51 filaments onto single-stranded DNA substrates generated during homologous recombination-based repair of DNA double-strand breaks and interstrand crosslinks[1][8][31][43]. This mediator function addresses a critical biological problem: replication protein A (RPA), a highly abundant and stable single-strand DNA binding protein, rapidly occupies and sequester exposed ssDNA with extraordinary avidity, effectively shielding the DNA substrate from RAD51 access and creating a substantial kinetic barrier to filament assembly[8][31][34]. In the absence of an intervention, RAD51 cannot effectively displace RPA from ssDNA, and productive recombination cannot proceed. The BRCA2 protein solves this problem through a multi-step mechanism in which it physically interacts with both RAD51 (through its BRC repeats) and single-stranded DNA (through its C-terminal DNA-binding domain), positioning these two components in favorable spatial and energetic configurations that enable RAD51 nucleoprotein filament formation to occur efficiently despite RPA occupancy[34].

Recent high-resolution single-molecule studies have demonstrated that BRCA2 functions as a molecular chaperone for RAD51, actually delivering preassembled dimeric nuclei of RAD51 directly to RPA-coated ssDNA, thereby accelerating the otherwise rate-limiting nucleation step of filament assembly to rates approaching those observed on naked ssDNA devoid of RPA[34]. This chaperoning activity represents a remarkable molecular accomplishment, as it enables the nucleation of RAD51 filaments at a 6.3-fold increased frequency near the ssDNA-dsDNA junction compared to conditions without BRCA2[34]. Following nucleation, BRCA2 facilitates unidirectional 3' to 5' directional growth of the RAD51 filament, with BRCA2 molecules ultimately capping the 3' end of the filament to prevent inappropriate extension onto double-stranded DNA[2][37][42]. This capping function is particularly important because RAD51 filaments that extend onto dsDNA regions would be nonproductive for homologous pairing and would represent a waste of cellular resources.

### Regulation of RAD51 Binding Activity

The mechanism by which BRCA2 BRC repeats regulate RAD51 binding displays remarkable sophistication, operating through what has been termed a "conformational switch" mechanism in which the engagement of BRC repeats with RAD51 influences the ATP hydrolysis activity of RAD51 and its ability to bind different DNA substrates[8][31]. The BRC1-4 repeats, through their high-affinity interaction with RAD51 monomers, inhibit the DNA-dependent ATP hydrolysis of RAD51, thereby slowing the dissociation of RAD51 from ssDNA and promoting stable filament nucleation and early growth[8][31]. Simultaneously, these same repeats reduce the affinity of RAD51 for double-stranded DNA, creating a situation in which RAD51 loaded onto BRC repeats exhibits preference for ssDNA substrates and avoids wasteful interactions with the surrounding dsDNA duplex[8][31]. This selective promotion of RAD51 binding to ssDNA while inhibiting its binding to dsDNA represents an elegant solution to the problem of substrate specificity, ensuring that recombination machinery is directed toward the sites of DNA damage where single-stranded regions have been generated rather than being inappropriately loaded onto intact double-helical DNA.

The interaction between individual BRC repeats and RAD51 is not static but displays remarkable plasticity depending on the nucleotide state and assembly status of RAD51[16][34]. The BRC1-4 repeats bind with higher affinity to free RAD51 monomers and RAD51 oligomers that have not yet assembled on DNA, whereas the BRC5-8 repeats exhibit preference for RAD51 that is already engaged in nucleoprotein filaments[16]. This functional specialization suggests an evolutionary optimization in which different BRC repeats have been selected to participate in distinct stages of recombination-mediated repair, creating a system in which BRCA2 can dynamically regulate RAD51 loading, extension, and stabilization in a temporally coordinated fashion.

### Filament Nucleation and Growth

The process by which BRCA2 facilitates RAD51 filament formation appears to involve multiple rounds of nucleation followed by gap-filling rather than progressive elongation from a single nucleation site[2][37][42]. Three-dimensional electron microscopy reconstructions have revealed that a BRCA2 dimer recruits two oppositely-oriented sets of RAD51 molecules, yet upon ssDNA binding, only one set of RAD51 can productively engage with the DNA due to the inherent polarity of the ssDNA substrate[2][37][42]. This architectural constraint creates a situation in which BRCA2 achieves efficiency through the formation of multiple nucleation clusters along the ssDNA length, each capable of nucleating RAD51 polymerization independently, with subsequent gap-filling to create a continuous filament[2]. This multi-site nucleation model explains how BRCA2 can efficiently overcome the kinetic barrier imposed by RPA despite the massive thermodynamic advantage RPA possesses in DNA binding.

The stimulation of RAD51-mediated DNA strand exchange is differentially regulated by the two classes of BRC repeats[16][43]. BRC1-4 repeats strongly stimulate RAD51-catalyzed strand exchange activity with an affinity-dependent relationship, in which BRC repeats with higher RAD51 binding affinity produce greater stimulation of strand exchange[16]. In contrast, BRC5-8 repeats, despite their ability to stabilize nascent RAD51-ssDNA filaments, do not substantially stimulate DNA strand exchange at the concentrations tested, suggesting their role is restricted to stabilization of already-assembled filaments rather than participation in the strand exchange catalysis itself[16]. This division of labor between BRC repeat classes appears functionally important for ensuring that nucleation and extension of RAD51 filaments are tightly coordinated with the subsequent strand exchange reaction that is essential for homologous recombination-mediated repair.

## Mechanism of Action in Homologous Recombination Pathway

### Integration with Other Recombination Proteins

The BRCA2 protein does not function in isolation but rather as a central node in a broader network of recombination-associated proteins that coordinate all aspects of homologous recombination-mediated DNA repair[43]. At the upstream end, BRCA2 interacts directly with the PALB2 protein (Partner and Localizer of BRCA2) through its N-terminal region, and this interaction is essential for BRCA2 localization to sites of DNA damage following ionizing radiation or other DNA-damaging stresses[15][43][55]. PALB2 itself associates with BRCA1 through a coiled-coil domain interaction, creating a hierarchical assembly in which BRCA1 serves as an upstream regulator that promotes the accumulation of PALB2 and BRCA2 at DNA-damage foci[55]. The BRCA1-PALB2-BRCA2 axis thus represents an integrated checkpoint for DNA damage recognition and response, with PALB2 functioning as the essential linker connecting BRCA1's early DNA damage sensing functions to BRCA2's recombination mediator activities[55].

BRCA2's interaction with the acidic protein DSS1 represents another critical regulatory partnership[44][47][51]. DSS1 binds to the BRCA2 C-terminal DNA-binding domain and is required for the stability of BRCA2 in cells, with mutations that disrupt DSS1 binding resulting in reduced protein levels and cellular dysfunction[44][47]. Beyond its stabilizing role, DSS1 appears to serve regulatory functions, including antagonizing multimerization of BRCA2 and promoting the monomeric form of the protein, which may be preferentially active for certain cellular functions[51]. DSS1 also appears to facilitate the displacement of RPA by RAD51 during homologous recombination by reducing RPA's affinity for ssDNA, providing another mechanism through which BRCA2-associated proteins enhance recombination efficiency[44].

### Interstrand Crosslink Repair

Beyond its well-established roles in double-strand break repair, BRCA2 participates in the Fanconi anemia (FA) DNA repair pathway that is specifically responsible for repair of interstrand crosslinks (ICLs)[9][19][22][43]. In this pathway, BRCA2 functions as FANCD1, the protein product of the FANCB2 gene in the Fanconi anemia complementation group, and participates in the downstream steps of ICL repair after initial nucleolytic unhooking of the lesion[9][19][22]. The role of BRCA2 in ICL repair involves its mediator function in directing RAD51 to sites of stalled replication forks where ICLs have been encountered, and importantly, recent evidence indicates that BRCA2 participates in protecting the DNA at ICL sites from inappropriate degradation by the DNA2 nuclease-WRN helicase complex[9][22]. This protection function appears to be distinct from BRCA2's role in protecting hydroxyurea-stalled replication forks, as indicated by studies of BRCA2 DNA-binding domain mutants discovered in Fanconi anemia patients that display loss of replication fork protection but only moderate deficiency in homologous recombination repair[9].

## Replication Fork Protection and Stabilization

### Mechanisms of Fork Protection

In addition to its established role as a mediator of homologous recombination, BRCA2 functions in protecting stalled replication forks from nucleolytic degradation, a process essential for maintaining genome stability when replication machinery encounters DNA damage or other obstacles that require transient fork arrest[9][43]. When DNA replication forks encounter obstacles such as interstrand crosslinks or are stalled by hydroxyurea treatment (which depletes dNTP pools), the exposed single-stranded DNA at these forks becomes vulnerable to attack by nucleolytic enzymes, particularly the MRE11 nuclease component of the MRE11-RAD50-NBS1 (MRN) complex[9][43]. BRCA2, working in concert with RAD51, protects these stalled replication forks by mechanisms that appear to prevent or limit the access of MRE11 to the replication fork, thereby preserving the integrity of the nascent DNA strand and maintaining the structural information required for subsequent fork restart[9][43].

The precise molecular mechanism by which BRCA2 and RAD51 protect replication forks from MRE11-dependent degradation remains incompletely understood, but appears to involve the formation of a protective nucleoprotein structure at the fork, possibly involving RAD51 filament assembly at the single-stranded DNA regions exposed at stalled forks[9]. This fork protection function has been shown to require the RAD51-interaction domains of BRCA2 but to be largely independent of the C-terminal DNA-binding domain, suggesting that the critical function involves BRCA2's ability to deliver RAD51 to fork sites rather than direct DNA binding by BRCA2 itself[9]. Notably, cells expressing BRCA2 mutations that substantially impair replication fork protection may retain near-normal homologous recombination repair capability, indicating that these two functions can be genetically separated and may involve distinct structural or mechanistic aspects of BRCA2's interactions with RAD51 and DNA[9].

### Distinct Protection Mechanisms for Different Fork Stalling Conditions

Recent research has revealed that BRCA2 participates in at least two mechanistically distinct replication fork protection processes, distinguished by the nature of the stalling agent and the specific nuclease that threatens fork integrity[9]. At hydroxyurea-induced stalled forks, BRCA2 and RAD51 work together to protect nascent DNA from MRE11-dependent exonucleolytic degradation, as evidenced by the fact that MRE11 inhibition or depletion rescues the nuclease sensitivity of BRCA2-deficient cells[9]. In contrast, at interstrand crosslink-induced stalled forks, BRCA2 protection operates through a mechanism that guards against degradation by the DNA2 nuclease-WRN helicase complex rather than MRE11[9]. This functional dichotomy suggests evolutionary optimization in which BRCA2 has been selected to respond to the specific nucleolytic threats posed by different types of replication stress, possibly through distinct protein-protein interactions or RAD51 assembly configurations that are specialized for each context.

## Cellular Localization and Nuclear Import

### Nuclear Localization and Cell Cycle-Dependent Expression

BRCA2 functions exclusively within the cell nucleus, where it localizes to discrete foci at sites of DNA damage in response to ionizing radiation or other genotoxic stress[10][45]. The protein is expressed in response to cell proliferation, with expression initiated before DNA synthesis, consistent with a role in preparing cells for replication-associated DNA damage responses[10][45]. Cell cycle analysis has revealed that BRCA2 mRNA expression is regulated tightly by the cell cycle, with maximum mRNA levels observed in late G1 and S phase, substantially lower levels in G0 and early G1, and moderate levels in G2/M[56][59]. This cell cycle-regulated expression pattern suggests that cellular BRCA2 activity is heightened precisely during the phases when DNA replication occurs and when homologous recombination-mediated repair is most active, providing a temporal coordination between DNA damage susceptibility and DNA repair capacity.

The subcellular localization of BRCA2 is not confined to nucleoplasm but includes dynamic association with additional cellular structures during specific phases of the cell cycle[26][29]. During interphase, BRCA2 localizes diffusely throughout the nucleus and concentrates in nuclear foci at sites of DNA damage[26]. During mitosis, BRCA2 associates with centrosomes, the spindle midzone, and the cytokinetic midbody, suggesting functions beyond canonical DNA repair[26][29]. At the midbody during abscission, BRCA2 localizes through interaction with the actin-binding protein Filamin A, and recruits endosomal sorting complex required for transport (ESCRT) proteins including Alix and Tsg101, participating in the final stages of cell division[29]. This extrarepair localization of BRCA2 and its association with cytokinesis machinery indicates that the protein participates in cellular processes beyond DNA damage response, suggesting a broader role in maintaining cell integrity through multiple stress conditions.

### Nuclear Import and DSS1-Dependent Localization

The nuclear import of BRCA2 is mediated through recognition of its three C-terminal nuclear localization signals by the classical nuclear import machinery involving importin-α and importin-β[1][7]. However, the regulation of BRCA2 nuclear accumulation extends beyond these intrinsic targeting signals to include control through interaction with DSS1, which masks a nuclear export signal (NES) that would otherwise promote nuclear export[44]. When DSS1 is bound to BRCA2, the protein accumulates in the nucleus with high efficiency, whereas variants of BRCA2 that fail to bind DSS1 effectively show reduced nuclear localization and accumulation in the cytoplasm[44]. This DSS1-dependent control of BRCA2 localization provides an additional layer of regulation in which the stability and activity of BRCA2 in the nucleus are linked to its interaction with a critical partner protein, ensuring that the protein remains in the compartment where DNA repair functions must occur.

## Cell Cycle Regulation and Checkpoint Control

### Phosphorylation-Dependent Regulation of RAD51 Interaction

The activity of BRCA2 in promoting homologous recombination is subject to sophisticated cell cycle-dependent regulation mediated by phosphorylation of a critical serine residue (Ser3291) in the C-terminal RAD51-binding domain[38][41]. During interphase, particularly in G2/M phase, cyclin A-CDK2 and cyclin B-CDK1 phosphorylate BRCA2 at Ser3291, a modification that blocks the interaction between BRCA2 and RAD51 through this C-terminal domain and suppresses homologous recombination repair[38][41]. This phosphorylation-mediated suppression of RAD51 binding appears to function as a checkpoint control mechanism that ensures homologous recombination is not activated at inappropriate times in the cell cycle when it might generate chromosomal rearrangements or other genomic instability.

Upon DNA damage, this phosphorylation is rapidly suppressed through a mechanism involving the degradation of CDC25A phosphatase, which maintains CDK2 activity[38]. The reduction in Ser3291 phosphorylation following DNA damage allows RAD51 to bind to the C-terminal domain of BRCA2, facilitating recruitment of RAD51 to damage sites and activating homologous recombination-mediated repair[38]. Interestingly, cyclin D1, which activates CDK4/6 in early G1, prevents the phosphorylation of BRCA2 Ser3291 by competing with cyclin A and cyclin B for binding to BRCA2, thereby maintaining the C-terminal RAD51-binding domain in a dephosphorylated, active state during the G1/S transition[38]. This intricate regulatory network ensures that the balance between suppression and activation of BRCA2-dependent homologous recombination is maintained by multiple cell cycle checkpoints and is responsive to both cell cycle phase and DNA damage signals.

### G2/M Checkpoint Control

Beyond its role as a mediator of homologous recombination, BRCA2 participates in the G2/M DNA damage checkpoint that arrests cells in G2 phase following DNA damage to prevent segregation of damaged chromosomes and maintain genome stability[1][20][23]. The BRCA1-PALB2-BRCA2 axis is essential for this checkpoint control, with BRCA1 playing a prominent role in both checkpoint activation and maintenance, while BRCA2 and PALB2 function particularly in checkpoint maintenance[20]. Interestingly, the G2/M checkpoint function of BRCA2 appears to operate through a mechanism distinct from its homologous recombination mediator function, as the checkpoint response is independent of CHK1 and CHK2 kinase phosphorylation, the apical kinases typically responsible for checkpoint control[20]. This suggests that BRCA2 participates in an alternative checkpoint signaling pathway that may operate through its interactions with PALB2 and other checkpoint-associated proteins.

## Meiotic Recombination Functions

### DMC1 Mediator Activity

Beyond its established roles in somatic cell homologous recombination, BRCA2 participates in meiotic recombination by functioning as a mediator of the meiosis-specific recombinase DMC1 (disrupted meiotic cDNA 1), a paralog of RAD51[25][28]. The interaction between BRCA2 and DMC1 maps to a domain in the central region of BRCA2 (approximately residues 2386-2411) that is distinct from the BRC repeats that mediate RAD51 interaction, indicating that BRCA2 possesses separate domains for binding and regulating the two recombinases[25]. This primary DMC1 interaction domain is highly conserved in mammalian BRCA2 proteins but is notably absent in BRCA2 orthologs from plants and invertebrates such as Arabidopsis and Caenorhabditis elegans, suggesting that the meiotic function of mammalian BRCA2 represents a derived characteristic that may enhance meiotic fidelity in complex organisms[25].

The BRC repeats also interact with DMC1, but with different affinities than with RAD51, suggesting that the same BRC repeat domains can participate in regulating both the somatic and meiotic recombinases[28]. Biochemically, BRCA2 stimulates DMC1-catalyzed DNA strand exchange activity through mechanisms similar to those employed for RAD51 stimulation, providing evidence that BRCA2 functions as a universal regulator of RAD51/DMC1 recombinase actions[25]. The physiological importance of BRCA2's meiotic function is underscored by the infertility phenotype of BRCA2-deficient mice, in which spermatocytes fail to progress beyond early prophase I of meiosis and oocytes display high frequencies of nuclear abnormalities[53].

## Protein-Protein Interactions and Multimeric Complexity

### Oligomerization and Conformational Plasticity

BRCA2 exists in cells in multiple oligomeric states, including both monomeric and dimeric forms, with the proportions of these states being regulated by binding to partner proteins and single-stranded DNA[51][54]. Biochemical and electron microscopic analysis has revealed that BRCA2 multimerization is counteracted by both DSS1 and ssDNA, which promote stabilization of monomeric forms of the protein[51]. The multimerization of BRCA2 involves self-interactions between the N- and C-terminal regions of the protein, which can be disrupted by DSS1 binding to the DNA-binding domain and by ssDNA engagement with the DNA-binding regions[51]. The functional significance of these different oligomeric states remains incompletely understood, though evidence suggests that the monomeric and oligomeric forms of BRCA2 may be differentially active for different cellular functions in recombinational DNA repair and replication fork stabilization[51].

The conformational flexibility of BRCA2 represents a remarkable molecular feature, with the N- and C-terminal regions identified as particularly flexible regions that significantly influence BRCA2 oligomerization and its interactions with binding partners[54]. Purified BRCA2 displays substantial rearrangements in its molecular architecture in response to binding with RAD51 and ssDNA, structural changes that are consistent with the protein containing intrinsically disordered regions[39]. This conformational plasticity may be important for BRCA2's ability to accommodate the binding of multiple partner proteins and to undergo the structural transitions necessary for its participation in the various stages of homologous recombination, from initial RAD51 nucleation through strand invasion and beyond.

### The BRCA1-PALB2-BRCA2 Complex

The integration of BRCA2 into a functional complex with BRCA1 and PALB2 represents a critical aspect of its cellular function, with PALB2 serving as the essential linker that directly associates with both proteins[15][55]. PALB2 contains an N-terminal coiled-coil domain that interacts directly with a coiled-coil motif in BRCA1, and a C-terminal WD40 domain that binds the N-terminus of BRCA2[15][55]. The formation of the BRCA1-PALB2-BRCA2 complex appears essential for localizing both PALB2 and BRCA2 to sites of DNA damage, as BRCA1 serves as an upstream regulator that promotes the accumulation of both PALB2 and BRCA2 at ionizing radiation-induced foci[55]. This hierarchical organization suggests that BRCA1 acts as a damage sensor that recruits the PALB2-BRCA2 recombination machinery to damage sites, with PALB2 functioning as an adaptor that bridges the two proteins and coordinates their activities.

Beyond its linker function, PALB2 contributes its own biochemical activities to the complex, including direct binding and stabilization of RAD51 filaments, promotion of strand invasion, and reduction of RPA-mediated inhibition of recombination[15]. The recruitment of PALB2 to DNA damage foci requires interaction with BRCA1, but the assembly of PALB2 nuclear foci is also promoted by additional factors including MDC1, RNF8, UIMC1 (RAP80), ABRAXAS, and RNF168, all proteins involved in BRCA1 recruitment, indicating that the assembly of the BRCA1-PALB2-BRCA2 complex is driven by multiple checkpoint signaling pathways[15]. This multi-layered recruitment mechanism suggests that the formation of this complex at DNA damage sites is a highly regulated process responsive to multiple forms of DNA damage and stress signals.

## Cancer Predisposition and Hereditary Breast and Ovarian Cancer

### Clinical Significance of BRCA2 Mutations

Heterozygous germline mutations in BRCA2 confer profound predisposition to breast, ovarian, pancreatic, prostate, and other malignancies, establishing BRCA2 as a classical tumor suppressor gene in which loss of function drives malignant transformation[1][3][49]. Women who inherit pathogenic BRCA2 variants have a lifetime risk of developing breast cancer exceeding 60%, substantially higher than the approximately 13% risk in the general population, and a lifetime ovarian cancer risk of approximately 13-29% compared to 1.1% in the general population[49]. The cancer predisposition associated with BRCA2 mutations follows the classic two-hit model of tumor suppression, in which the inherited heterozygous mutation in one allele is typically not sufficient to transform cells, but when combined with somatic loss of the remaining wild-type allele through deletion, point mutation, or epigenetic silencing, homozygous or compound deficiency results in genome instability, loss of checkpoint control, and malignant transformation[1][3].

The relationship between BRCA2 mutation location and cancer risk has been examined in multiple studies, with evidence suggesting that some structural domains may be associated with differential cancer predisposition phenotypes, though this remains an area of active investigation[46]. Breast cancers developing in BRCA2 mutation carriers exhibit distinct biological characteristics, including elevated frequencies of hormone receptor expression (particularly estrogen receptor positivity in a subset of BRCA2 carriers) in contrast to BRCA1-associated breast cancers which show higher frequencies of triple-negative phenotypes[49]. Male BRCA2 carriers show substantially elevated breast cancer risk (lifetime risk approximately 5-6%) compared to the general male population (approximately 0.1%), a recognition that has important implications for genetic screening and surveillance of male family members of BRCA2 mutation carriers[49].

### Biallelic BRCA2 Mutations and Fanconi Anemia

Individuals who inherit pathogenic BRCA2 variants in both alleles (biallelic mutations) develop Fanconi anemia, a rare inherited disorder characterized by congenital abnormalities, chromosome fragility, progressive bone marrow failure, and substantially elevated cancer predisposition, particularly to leukemia and solid tumors, often presenting in childhood[3][19][22]. The severity of the Fanconi anemia phenotype typically exceeds that of heterozygous BRCA2 mutation carriers, reflecting the more severe compromise in DNA repair and genome stability that results from complete loss of BRCA2 function. This distinction between monoallelic and biallelic BRCA2 mutations highlights the critical importance of BRCA2 in maintaining genome stability and demonstrates the dose-dependent effects of BRCA2 deficiency on cancer predisposition.

## Therapeutic Implications and PARP Inhibitor Sensitivity

### Synthetic Lethality and Precision Medicine

The discovery that BRCA2-deficient cells exhibit synthetic lethality with poly(ADP-ribose) polymerase (PARP) inhibitors has revolutionized the therapeutic approach to BRCA2-associated malignancies[33][36]. PARP inhibitors block the base excision repair pathway by preventing PARP-catalyzed ADP-ribosylation of DNA damage response proteins, leading to accumulation of single-strand breaks in DNA[33][36]. In normal cells with functional BRCA2, these single-strand breaks are converted to double-strand breaks during DNA replication, but are then repaired through homologous recombination mediated by BRCA2-RAD51 complexes, allowing cells to survive[33][36]. However, in BRCA2-deficient cancer cells, the defective homologous recombination machinery cannot efficiently repair the accumulating DNA damage from PARP inhibition, resulting in excessive double-strand breaks and cell death[33][36].

Clinically, PARP inhibitors have shown substantial benefit in the treatment of BRCA1/2-mutant breast, ovarian, and pancreatic cancers, with FDA-approved agents including olaparib (Lynparza), which was the first PARP inhibitor approved and has demonstrated substantial clinical benefit[33][36]. The success of PARP inhibitor therapy in BRCA-deficient tumors exemplifies the power of precision medicine approaches in which detailed knowledge of molecular defects in cancer cells can be leveraged to design therapeutic strategies that selectively target cancer cells while minimizing effects on normal tissues[33]. However, resistance to PARP inhibitors can emerge through multiple mechanisms, including secondary BRCA2 mutations that restore protein function, alterations in replication fork protection pathways, and modulation of the homologous recombination machinery[33].

### Resistance Mechanisms and Future Directions

The development of PARP inhibitor resistance in BRCA2-mutant cancers has illuminated additional aspects of BRCA2 function and has revealed multiple pathways through which cancer cells can compensate for BRCA2 deficiency[33]. Secondary BRCA2 mutations that result in restoration of protein function represent the most common mechanism of resistance, occurring through frameshift-suppressing mutations that restore the open reading frame, or through mutations that convert stop codons to sense codons, allowing translation of full-length or nearly full-length protein[33]. This observation demonstrates that the catalytic function of BRCA2 in DNA repair is the critical target of synthetic lethality, and that restoration of even modest levels of BRCA2 activity can substantially enhance chemotherapy and PARP inhibitor resistance[33].

Understanding the molecular mechanisms by which BRCA2 exerts its tumor suppressor functions has revealed additional therapeutic opportunities beyond PARP inhibitors. DNA-damaging chemotherapy agents such as cisplatin remain highly effective in BRCA2-deficient tumors because they generate double-strand breaks that cannot be repaired efficiently through homologous recombination, making them synthetically lethal with BRCA2 deficiency through a mechanism similar to PARP inhibitors[49]. Emerging evidence suggests that targeting components of the DNA2-WRN complex that degrades stalled replication forks in BRCA2-deficient cells, or inhibiting components of the Fanconi anemia pathway, may provide additional therapeutic approaches in BRCA2-mutant malignancies[33][43].

## Structural Features and DNA Binding Mechanisms

### Single-Stranded DNA Binding Specificity

The C-terminal DNA-binding domain of BRCA2 exhibits strong preference for single-stranded DNA compared to double-stranded DNA, a specificity that is critical for its function as a mediator of recombination-mediated DNA repair[2][34][37][42]. This preference appears to arise through the combined contributions of multiple OB folds that interact cooperatively with ssDNA, with OB2 and OB3 providing the primary binding interactions[2][14]. The binding of ssDNA to BRCA2 is not sequence-specific but rather length-dependent, with the protein requiring approximately 40 nucleotides for weak binding and more than 70 nucleotides for maximal affinity, suggesting that BRCA2 recognizes the extended single-stranded DNA regions characteristic of those generated during DNA damage processing[2][42].

The binding of ssDNA to the BRCA2 dimer involves an architectural arrangement in which the ssDNA binds along the long axis of the dimeric protein, positioned such that only one of the two oppositely-oriented sets of RAD51 molecules bound to the BRCA2 dimer can form productive contacts with the DNA[2][37][42]. This asymmetric arrangement appears mechanistically important for ensuring unidirectional growth of the RAD51 filament, with one end of the filament growing as RAD51 monomers are added, while the opposite end is capped by BRCA2, preventing extension in that direction[2][37][42]. Recent studies suggest that BRCA2 may preferentially engage at the 5' terminus of ssDNA-dsDNA junctions, though the protein does not show absolute preference for junction structures as do some orthologs such as the fungal Brh2 protein[31][34].

### DSS1-Mediated Regulation of DNA Binding

The interaction of BRCA2 with the small acidic protein DSS1 exerts substantial regulatory control over the DNA-binding activity of BRCA2, with DSS1 appearing to modulate the accessibility of DNA binding sites within the BRCA2 structure[44]. The DSS1 protein binds to the C-terminal DNA-binding domain of BRCA2, and this interaction both stabilizes the protein and influences its conformational state in ways that affect DNA binding[44]. Some evidence suggests that DSS1 acts as a negative modulator of DNA binding by BRCA2, occupying or blocking access to DNA-binding surfaces within the DNA-binding domain, thereby regulating the extent to which BRCA2 engages with DNA[44]. This regulatory mechanism provides another layer of control in which the DNA-binding activity of BRCA2 is not merely determined by intrinsic protein properties but is actively regulated by interaction with a partner protein, allowing cells to modulate the intensity of BRCA2-ssDNA interactions in response to cellular conditions.

The variant BRCA2 R2645G, identified in breast cancer patients and located near the DSS1 binding site, unexpectedly increases the ssDNA binding activity of BRCA2 while maintaining normal DSS1 binding, resulting in enhanced DNA recombination activity that paradoxically increases cancer susceptibility[44]. This observation demonstrates that optimal BRCA2 function requires tightly regulated ssDNA binding activity, and that enhancement of binding affinity beyond wild-type levels results in hyperrecombination phenotypes associated with chromosomal instability and increased cancer risk[44]. This finding illustrates a principle that tumor suppressor functions often require fine-tuned levels of activity, with both loss and gain of function potentially driving malignant transformation through distinct mechanisms.

## Conformational Changes and Structural Transitions

### Conformational Rearrangement Upon Binding

The BRCA2 protein undergoes substantial conformational rearrangements in response to binding with its partner proteins RAD51 and ssDNA, changes that are believed to be important for the functional transitions required during homologous recombination[39][42]. Biochemical and biophysical studies employing atomic force microscopy and electron microscopy have documented that purified BRCA2 protein displays remarkable structural plasticity, with the protein adopting multiple conformations depending on its binding partners[39][54]. These conformational changes may serve important regulatory functions, allowing BRCA2 to transition between states optimized for RAD51 nucleation, filament extension, and strand invasion, with each stage of the recombination process potentially requiring distinct BRCA2 configurations.

The C-terminal and DNA-binding domains of BRCA2, despite being functionally distinct and separable by mutagenesis, appear to be structurally coupled, as deletions of one domain substantially impair the conformational rearrangements triggered by binding partners[39]. This coupling suggests that the overall three-dimensional architecture of BRCA2 is important for its ability to respond to signals from binding partners and to undergo the structural transitions necessary for its biochemical functions. The considerable flexibility of the N- and C-terminal regions of BRCA2 may allow these domains to sample multiple conformations, facilitating the protein's ability to accommodate different binding partners and substrates at different stages of the recombination process[54].

## Transcriptional Regulation and Expression Control

### Endocrine Regulation and Estrogen Receptor Interaction

Recent evidence indicates that BRCA2 participates in transcriptional regulation through interaction with the estrogen receptor and involvement in the control of estrogen-responsive genes[27]. BRCA2 binds to the estrogen receptor upon estradiol treatment and interacts with proteins that regulate estrogen-dependent transcription, including the coactivator SRC-1[27]. Through these interactions, BRCA2 appears to suppress the transcriptional activation of the pS2 gene, a target gene of the estrogen receptor, suggesting a negative regulatory role of BRCA2 in estrogen-dependent transcription[27]. This novel function of BRCA2 beyond DNA repair may have implications for understanding the particular susceptibility of BRCA2 mutation carriers to hormone receptor-positive breast cancers and may suggest that some aspects of BRCA2 function in breast tissue are related to hormonal responsiveness rather than solely to DNA damage response.

### Post-transcriptional Regulation

The expression of BRCA2 is subject to post-transcriptional regulation through microRNA-mediated mechanisms, with miR-19a and miR-19b identified as negative regulators of BRCA2 mRNA expression[30]. These microRNAs target a response element in the 3' untranslated region of BRCA2 mRNA, and overexpression of miR-19a or miR-19b in multiple cell lines results in decreased BRCA2 mRNA and protein levels[30]. The extent of miRNA-mediated suppression appears to be cell-type dependent, with the greatest effects observed in pancreatic cancer cell lines, suggesting that miR-19a/b-mediated BRCA2 suppression may be particularly relevant in specific tissue contexts[30]. This microRNA-mediated regulation of BRCA2 expression suggests that dysregulation of miR-19a/b levels in tumors could contribute to reduced BRCA2 expression and consequent genomic instability, providing an alternative mechanism through which BRCA2 function could be compromised in cancers without somatic mutations in the BRCA2 gene itself.

## Conclusion: Integration of BRCA2 Functions in Genome Maintenance

The BRCA2 protein represents a remarkable molecular machine that integrates multiple functions essential for maintaining genomic stability across multiple cellular contexts including homologous recombination-mediated repair of double-strand breaks and interstrand crosslinks, protection of stalled replication forks, cell cycle checkpoint control, and meiotic recombination in germ cells[1][8][9][20][25][31]. The protein's large size and complex modular architecture enable it to serve as a central node in networks of protein-protein interactions that coordinate the activities of numerous DNA repair and checkpoint proteins, with distinct domains specialized for binding specific partners including RAD51, RAD51 (DMC1), PALB2, DSS1, and multiple other cellular proteins[1][15][25][43][55]. The cell cycle-regulated phosphorylation of BRCA2 and its dynamic localization to different cellular structures throughout the cell cycle indicate that BRCA2 activity is tightly coordinated with cellular proliferation and the specific requirements of different phases of the cell cycle[10][38][56].

The functional importance of BRCA2 in maintaining genome stability is underscored by the severe consequences of its inactivation, ranging from embryonic lethality in complete knockout organisms, to Fanconi anemia in humans with biallelic mutations, to dramatically elevated cancer predisposition in heterozygous carriers[1][3][50][53]. The discovery of synthetic lethality between BRCA2 deficiency and PARP inhibitors has provided powerful therapeutic tools for treating BRCA2-associated malignancies, though the emergence of resistance mechanisms has illuminated the multiple pathways through which cancer cells can compensate for BRCA2 loss[33]. Future advances in understanding BRCA2 function are likely to come from studies that integrate structural, biochemical, and cellular approaches to clarify the molecular mechanisms by which different BRCA2 domains and post-translational modifications regulate the protein's interactions with its diverse binding partners and substrates. Additionally, continued investigation of how BRCA2 integrates DNA damage responses with cell cycle control, replication fork dynamics, and transcriptional regulation may reveal additional aspects of this multifunctional protein's role in cancer prevention and identify new therapeutic opportunities for patients carrying BRCA2 mutations.

## Citations

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8307705/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4222816/
3. https://medlineplus.gov/genetics/gene/brca2/
4. https://www.ncbi.nlm.nih.gov/gene/675
5. https://geneglobe.qiagen.com/us/knowledge/gene/ENSG00000139618
6. https://pubmed.ncbi.nlm.nih.gov/15546503/
7. https://pubmed.ncbi.nlm.nih.gov/10733923/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3647347/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC7263144/
10. https://pubmed.ncbi.nlm.nih.gov/9407955/
11. https://pubmed.ncbi.nlm.nih.gov/11239456/
12. https://genesdev.cshlp.org/content/34/11-12/832
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC20253/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC2906097/
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6693662/
16. https://www.pnas.org/doi/10.1073/pnas.1106971108
17. https://www.ebi.ac.uk/interpro/entry/interpro/IPR048262
18. https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/palb2/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3403008/
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6408219/
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6754178/
22. https://fanconi.org/clinical-care-guidelines/the-fanconi-anemia-dna-repair-pathway/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3128973/
24. https://pubmed.ncbi.nlm.nih.gov/31433991/
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC1894777/
26. https://www.science.org/cms/asset/3110d7af-55c3-46e5-a9c4-e8215752e3bd/pap.pdf
27. https://pubmed.ncbi.nlm.nih.gov/34952473/
28. https://www.pnas.org/doi/10.1073/pnas.1601691113
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3419138/
30. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2016.00143/full
31. https://academic.oup.com/nar/article/52/7/3837/7624075
32. https://www.oncoscience.us/article/610/text/
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC10083600/
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7664306/
35. https://www.youtube.com/watch?v=vwZ07CX7ZKU
36. https://pubmed.ncbi.nlm.nih.gov/25282148/
37. https://pmc.ncbi.nlm.nih.gov/articles/PMC6538526/
38. https://elifesciences.org/articles/67926
39. https://www.uniprot.org/uniprotkb/P51587/entry
40. https://pubmed.ncbi.nlm.nih.gov/15800615/
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC8394001/
42. https://academic.oup.com/nar/article/52/12/6964/7492909
43. https://aacrjournals.org/clincancerres/article/24/2/326/122963/Location-of-Mutation-in-BRCA2-Gene-and-Survival-in
44. https://pubmed.ncbi.nlm.nih.gov/14580353/
45. https://aacrjournals.org/cancerres/article/57/24/5485/503732/Nuclear-Location-and-Cell-Cycle-Regulation-of-the
46. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
47. https://pubmed.ncbi.nlm.nih.gov/10819537/
48. https://academic.oup.com/nar/article/48/14/7818/5866100
49. https://www.ncbi.nlm.nih.gov/books/NBK1247/
50. https://pubmed.ncbi.nlm.nih.gov/14660434/
51. https://pmc.ncbi.nlm.nih.gov/articles/PMC7515699/
52. https://pmc.ncbi.nlm.nih.gov/articles/PMC2750839/
53. https://pubmed.ncbi.nlm.nih.gov/8840967/
54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8799590/
55. https://pubs.acs.org/doi/10.1021/acschembio.5c00111
56. https://aacrjournals.org/cancerres/article-pdf/56/20/4590/2461850/cr0560204590.pdf
57. https://pmc.ncbi.nlm.nih.gov/articles/PMC3446350/